肝硬化急性失代偿患者血浆微生物游离DNA的预后与治疗意义
本研究对129例肝硬化急性失代偿患者行血浆宏基因组二代测序,发现74.4%可检出微生物,其中非嗜肝病毒以巨细胞病毒最常见,并与经验性抗生素疗效、进展为慢加急性肝衰竭及90天死亡相关;验证队列中巨细胞病毒检出率为24.1%,3例接受更昔洛韦治疗者临床缓解。
要点
- 肝硬化急性失代偿患者血浆mNGS可检出非嗜肝病毒,巨细胞病毒最常见。
- 非嗜肝病毒检出与经验性抗生素疗效、慢加急性肝衰竭进展及90天死亡相关。
- 验证队列巨细胞病毒检出率24.1%,3例更昔洛韦探索性治疗后临床缓解。
核心结论
- 研究结果提示非嗜肝病毒可能在肝硬化急性失代偿病程复杂化中起致病作用。
- 尚需进一步验证以确定是否应将其纳入肝硬化急性失代偿患者的常规管理。
研究设计与样本
- 研究队列纳入129例肝硬化急性失代偿患者行血浆mNGS检测。
- 对照包括10名健康志愿者及稳定肝硬化20例、严重脓毒症39例、血液系统恶性肿瘤81例。
- 验证队列58例进行人巨细胞病毒再激活验证检测并开展探索性治疗。
主要发现
- 研究队列中74.4%(96/129)患者检出188种微生物,包括病毒58.0%、细菌34.1%、真菌7.4%、衣原体0.5%。
- 急性失代偿患者中鉴定出非嗜肝病毒特征,巨细胞病毒为最常见非嗜肝病毒。
- 巨细胞病毒与非嗜肝病毒特征与经验性抗生素治疗的临床效果、进展为慢加急性肝衰竭及90天死亡相关。
- 慢加急性肝衰竭患者的非嗜肝病毒特征与脓毒症及血液系统恶性肿瘤患者相似。
- 验证队列中巨细胞病毒检出率为24.1%(14/58),14例中9例经实时PCR或pp65抗原血症检测进一步验证。
关键数值与推荐
- 3例巨细胞病毒再激活患者以探索性方式接受更昔洛韦治疗并出现临床缓解。
临床怎么用
- 作者认为,对非嗜肝病毒尤其是巨细胞病毒的常规筛查可能有助于肝硬化急性失代偿患者的管理。
- 作者指出尚需进一步验证以确定是否应将其纳入肝硬化急性失代偿患者的常规管理。
局限性
- 原文指出尚需进一步验证以确定非嗜肝病毒检测是否应纳入肝硬化急性失代偿患者的常规管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Although the effect of bacterial infection on cirrhosis has been well-described, the effect of non-hepatotropic virus (NHV) infection is unknown. This study evaluated the genome fragments of circulating microorganisms using metagenomic next-generation sequencing (mNGS) in individuals with acute decompensation (AD) of cirrhosis, focusing on NHVs, and related the findings to clinical outcomes. METHODS: Plasma mNGS was performed in 129 individuals with AD of cirrhosis in the study cohort. Ten healthy volunteers and 20, 39, and 81 individuals with stable cirrhosis, severe sepsis and hematological malignancies, respectively, were enrolled as controls. Validation assays for human cytomegalovirus (CMV) reactivation were performed in a validation cohort (n = 58) and exploratory treatment was instituted. RESULTS: In the study cohort, 188 microorganisms were detected in 74.4% (96/129) of patients, including viruses (58.0%), bacteria (34.1%), fungi (7.4%) and chlamydia (0.5%). A NHV signature was identified in individuals with AD, and CMV was the most frequent NHV, which correlated with the clinical effect of empirical antibiotic treatment, progression to acute-on-chronic liver failure, and 90-day mortality. The NHV signature in individuals with acute-on-chronic liver failure was similar to that in those with sepsis and hematological malignancies. CMV was detected in 24.1% (14/58) of patients in the validation cohort. Of the 14 cases with detectable CMV by mNGS, nine were further validated by real-time PCR or pp65 antigenemia testing. Three patients with CMV reactivation received ganciclovir therapy in an exploratory manner and experienced clinical resolutions. CONCLUSIONS: The results of this study suggest that NHVs may play a pathogenic role in complicating the course of AD. Further validation is needed to define whether this should be incorporated into the routine management of individuals with AD of cirrhosis. IMPACT AND IMPLICATIONS: A non-hepatotropic virus (NHV) signature, which was similar to that in individuals with sepsis and hematological malignancies, was identified in individuals with acute decompensation of cirrhosis. The detected viral signature had clinical correlates, including clinical efficacy of empirical antibiotic treatment, progression to acute-on-chronic liver failure and short-term mortality. Cytomegalovirus reactivation, which is treatable, may adversely affect clinical outcomes in some individuals with decompensated cirrhosis. Routine screening for NHVs, especially cytomegalovirus, may be useful for the management of individuals with acute decompensation of cirrhosis.
引用
- Li B, Hong C, Fan Z, et al. Prognostic and therapeutic significance of microbial cell-free DNA in plasma of people with acute decompensation of cirrhosis. J Hepatol. 2022. PMID: 36309130. doi:10.1016/j.jhep.2022.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。